Literature DB >> 2384103

Dynamic quantitative bone scintigraphy in patients with prostatic carcinoma treated by orchiectomy.

G M Sundkvist1, L Ahlgren, B Lilja, S Mattsson, P A Abrahamsson.   

Abstract

Dynamic quantitative bone scintigraphy was performed on 31 men with prostatic carcinoma before orchiectomy as well as 2 weeks, 2 and 6 months postoperatively. After injection of technetium methylene diphosphonate Tc 99m (99mTc-MDP) the count rate was recorded as serial images over the lower thoracic and all the lumbar vertebrae from 1 to 240 min post-injection. Thirteen men had normal bone scintigrams with no changes in 99mTc-MDP content at the four different investigation times. Eighteen men had skeletal metastases. Throughout the study half of the abnormal vertebrae in these patients showed an abnormal count rate after only 6 min post-injection. After 1 h it was possible in almost all abnormal vertebrae to predict abnormal bone uptake. In response to therapy a "flare phenomenon" with an increase in count rate was seen 2 weeks after orchiectomy followed by a decrease 2 months postoperatively in most of the abnormal vertebrae. The count rate decreased even below the pre-operative level after 6 months. Also, the normal vertebrae in the patients with skeletal metastases showed a tendency towards the flare phenomenon, which was not seen in patients with normal bone scintigrams.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2384103     DOI: 10.1007/bf00998167

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  10 in total

Review 1.  Angiogenic factors.

Authors:  J Folkman; M Klagsbrun
Journal:  Science       Date:  1987-01-23       Impact factor: 47.728

2.  Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan.

Authors:  M S Soloway; S W Hardeman; D Hickey; J Raymond; B Todd; S Soloway; M Moinuddin
Journal:  Cancer       Date:  1988-01-01       Impact factor: 6.860

3.  Dynamic studies with 99mTc-HEDP in normal subjects and in patients with bone tumors.

Authors:  D L Citrin; R G Bessent; E McGinley; D Gordon
Journal:  J Nucl Med       Date:  1975-10       Impact factor: 10.057

4.  Skeletal blood flow: implications for bone-scan interpretation.

Authors:  N D Charkes
Journal:  J Nucl Med       Date:  1980-01       Impact factor: 10.057

5.  Metastatic bone cancer.

Authors:  C R Wirth
Journal:  Curr Probl Cancer       Date:  1979-05       Impact factor: 3.187

6.  Bone scan flare predicts successful systemic therapy for bone metastases.

Authors:  R E Coleman; G Mashiter; K B Whitaker; D W Moss; R D Rubens; I Fogelman
Journal:  J Nucl Med       Date:  1988-08       Impact factor: 10.057

7.  Studies of skeletal tracer kinetics. III. Tc-99m(Sn)methylenediphosphonate uptake in the canine tibia as a function of blood flow.

Authors:  V V Sagar; J M Piccone; N D Charkes
Journal:  J Nucl Med       Date:  1979-12       Impact factor: 10.057

8.  Efficacy of follow-up bone scans in carcinoma of the prostate.

Authors:  D Corrie; J H Timmons; J M Bauman; I M Thompson
Journal:  Cancer       Date:  1988-06-15       Impact factor: 6.860

9.  Repeated quantitative bone scintigraphy in patients with prostatic carcinoma treated with orchiectomy.

Authors:  G M Sundkvist; L Ahlgren; B Lilja; S Mattsson; P A Abrahamsson; L B Wadström
Journal:  Eur J Nucl Med       Date:  1988

10.  The dedifferentiation of metastatic prostate carcinoma.

Authors:  P N Brawn; V O Speights
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

  10 in total
  2 in total

1.  Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.

Authors:  Charles J Ryan; Shreya Shah; Eleni Efstathiou; Matthew R Smith; Mary-Ellen Taplin; Glenn J Bubley; Christopher J Logothetis; Thian Kheoh; Christine Kilian; Christopher M Haqq; Arturo Molina; Eric J Small
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  The flare phenomenon: far from fair and square.

Authors:  W D van Schelven; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1994-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.